Form 4 for DFTX Definium Therapeutics, Inc.
Accepted 2022-08-15 00:00:00 ET · period of report 2022-08-11 · accession 0000899243-22-028727 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-08-15 | 2022-08-11 | DFTX | Bruhn Suzanne Louise | Dir | A - Grant | $0.00 | +89.3K | 89.3K | New | $0 |
| DM | 2022-08-15 | 2022-08-11 | DFTX | Bruhn Suzanne Louise | Dir | A - Grant | $0.00 | +624.7K | 121.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2022-08-11 | A | A | 89,286 | $0.00 | 89,286 | D | — | — | (F1) These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one Common Share of the Issuer. These RSUs will vest in three equal annual installments over such three-year period; provided, that in the event that the Reporting Person's continuous service as a member of the Board terminates for any reason other than for cause after the first anniversary of the grant date, a portion of these RSUs that would have vested on the next annual vesting date following the date of departure will immediately vest in full as of the date of termination of service on a prorated basis. |
| 2 | Derivative | Director's Deferred Share Units | 2022-08-11 | A | A | 503,773 | — | 503,773 | D | — · — to — | — Common Shares | (F4) Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. DDSUs will vest 1/3 on August 11, 2023, with the remaining portion vesting in equal monthly installments over the two years thereafter. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Common Share). Pursuant to the Plan, the fair market value of a Common Share is equal to the volume weighted average trading price of a Common Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). |
| 3 | Derivative | Stock Option (Right to Buy) | 2022-08-11 | A | A | 120,968 | $0.00 | 120,968 | D | $0.66 · — to 2032-08-10 | 120,968 Common Shares | (F2) The option grant has an exercise price of $0.84 Canadian Dollars. This represents the exercise price in United States Dollars. (F3) The shares underlying the option shall vest and become exercisable 1/3 on August 11, 2023, with the remaining portion vesting in equal monthly installments over the two years thereafter, subject to the Reporting Person providing continuous service to the Issuer on each such date. |